Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given a consensus recommendation of “Buy” by the twelve research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $92.44.

Several equities analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. BTIG Research upped their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd.

Janux Therapeutics Stock Up 8.8 %

Shares of Janux Therapeutics stock opened at $31.81 on Thursday. The stock’s fifty day moving average is $39.91 and its two-hundred day moving average is $47.17. The company has a market capitalization of $1.88 billion, a PE ratio of -27.19 and a beta of 3.23. Janux Therapeutics has a 52 week low of $28.92 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Plato Investment Management Ltd increased its holdings in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Janux Therapeutics in the fourth quarter valued at about $59,000. Avanza Fonder AB acquired a new position in shares of Janux Therapeutics in the fourth quarter valued at about $139,000. Finally, Meeder Asset Management Inc. acquired a new position in shares of Janux Therapeutics in the fourth quarter valued at about $159,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.